Stock performance

搜索文档
CarMax Stock Stalls on Q2 Earnings Setback
Schaeffers Investment Research· 2025-09-25 15:11
Shares of CarMax Inc (NYSE:KMX) were last seen in a 22.2% hole, trading at $44.37 after missing fiscal second-quarter expectations, reporting earnings of $0.64 on revenue of $6.59 billion. The company saw declines across the board, most notably in its wholesale and used vehicle segments. Wedbush downgraded KMX from "outperform" to "neutral" in response, and slashed its price target to $54 from $84.The equity has had a rough go of late, on track to extend its losing streak to five sessions and mark one of it ...
AutoZone Stock Gaps Lower After Quarterly Profit Miss
Schaeffers Investment Research· 2025-09-23 15:12
Shares of AutoZone Inc (NYSE:AZO) were last seen down 2.9% to trade at $3,990, after the company missed fiscal fourth-quarter earnings expectations. Revenue came in above estimates, though, as the automotive parts and accessories retailer also reported strong same-store sales growth.AZO is extending a pullback from its Sept. 11, all-time high of $4,388.11 as it gaps further below the 20-day moving average. The equity earlier slipped to its lowest level since mid-August, but still carries a 33.4% year-over-y ...
Micron Technology Inc. (NASDAQ:MU) Price Target and Stock Performance Analysis
Financial Modeling Prep· 2025-09-22 15:04
Brian Chin from Stifel Nicolaus sets a price target of $173 for Micron Technology Inc. (NASDAQ:MU), indicating a potential increase of 6.31% from its current price.The stock has shown notable volatility with a recent drop of 3.63% during an afternoon trading session, despite an overall upward trend in 2025.Micron's market capitalization is approximately $182.12 billion, with a trading volume of 37.31 million shares, underscoring significant investor interest and market presence.Micron Technology Inc. (NASDA ...
Is FactSet Research Stock Underperforming the Dow?
Yahoo Finance· 2025-09-22 13:55
FactSet Research Systems Inc. (FDS), headquartered in Norwalk, Connecticut, has long been a cornerstone for the investment community, offering a digital platform and enterprise solutions that cater to portfolio analytics, data management, and reporting workflows. With a market capitalization hovering around $10.9 billion, the company comfortably resides in the “large-cap” category, a tier reserved for the heavyweights valued at $10 billion or more. Its suite of services spans configurable desktop and mobi ...
Beyond Nvidia: Can Arm Stock Hit $210 Next Year?
247Wallst· 2025-09-17 18:45
Nvidia (NASDAQ:NVDA) is a generational performer and the stock still has plenty of room to run, even as a $4.32 trillion company. ...
What's Next For Estée Lauder's Stock?
Forbes· 2025-09-15 15:21
股价表现 - 过去一周股价下跌6% 连续5个交易日下跌[2][3] - 市值在过去5天内蒸发约19亿美元 当前市值约300亿美元[3] - 较2024年底水平仍上涨13.1% 同期标普500指数上涨11.9%[3] 财务业绩 - 第四季度净销售额同比下降12%[2] - 盈利预测低于分析师预期[2] - 关税可能造成1亿美元影响[2] 业务概况 - 公司主营护肤、彩妆、香水和护发产品 包括保湿霜、精华液、洁面产品和香水等[4] - 产品在全球范围内销售[4] 市场比较 - 当前标普500成分股中49只股票连续3天以上上涨 22只连续3天以上下跌[7] - 持续疲软可能反映情绪变化或更深层担忧[6]
Lululemon Stock May Be Down 57% This Year, But Is It Out?
Yahoo Finance· 2025-09-15 12:55
公司业绩表现 - 2025年第二季度销售额增长 但稀释后每股收益(EPS)仅下降1.5% [1] - 毛利率维持在历史区间范围内 显示盈利能力保持稳定 [1] - 因进口关税影响 2025年全年毛利率预计遭受2.4亿美元冲击 [5] 财务指引调整 - 全年营收指引从年初112亿美元下调至110亿美元(最高值) [6] - 全年EPS指引从14.95-15.15美元大幅下调至12.77-12.97美元 [7] - 指引中位数下调幅度达14% 反映盈利能力显著承压 [7] 市场表现与投资者情绪 - 公司股票位列2025年标普500指数表现最差成分股之一 [3] - 投资者担忧公司最佳增长阶段已结束 导致股价表现疲弱 [3] - 北美核心市场增长停滞 部分因前期高基数效应所致 [5] 品牌价值与竞争优势 - 公司净推荐值(NPS)达42分 显示品牌仍拥有忠实客户群体 [10] - NPS评分保持稳定 未出现品牌吸引力急剧下滑迹象 [10] - 海外生产集中越南 供应链结构面临关税政策持续影响 [5]
Evolution Petroleum (EPM) Q4 Earnings Preview: What You Should Know Beyond the Headline Estimates
ZACKS· 2025-09-12 14:16
核心财务预期 - 华尔街分析师预计公司季度每股收益为0.02美元 同比下滑33.3% [1] - 预计季度收入为2115万美元 同比下降0.4% [1] - 过去30天内未出现每股收益预期修正 表明分析师维持初始预测 [1] 关键运营指标预测 - 预计日均油气产量为7120桶油当量 低于去年同期的7209桶 [4] - 预计天然气液体平均销售价格为23.57美元 较去年同期的29.08美元下降 [4] - 预计原油平均销售价格为59.79美元 较去年同期的76.49美元显著下降 [5] 市场表现与评级 - 公司股价过去一个月上涨4.4% 表现优于标普500指数的3.4%涨幅 [5] - 公司获得Zacks第三级持有评级 预期表现将与整体市场保持一致 [5]
Hims & Hers Stock Jumps On Long-Awaited Foray Into Testosterone
Investors· 2025-09-10 15:23
核心事件 - 远程医疗巨头Hims & Hers Health宣布推出备受期待睾酮替代疗法TRT 导致公司股价周三大涨近7%至51.07美元 突破50日移动平均线[1][3] - 公司与私营企业Marius Pharmaceuticals达成合作 将提供四种治疗方案 具体定价尚未最终确定[2] 产品布局 - 2026年开始提供口服药物Kyzatrex 该药物可恢复96%男性睾酮水平 平均使游离睾酮翻倍[4] - 2025年计划推出注射型睾酮 即日起销售复合型恩氯米芬及他达拉非组合药物[4] - 患者从家庭血液检测开始 数日内获得结果并制定治疗方案[5] 定价策略 - 根据Leerink Partners分析师Michael Cherny预测 价格区间可能为每月99-199美元[2] - 具体方案包括:10个月计划每月99美元 5个月计划每月139美元 3个月计划每月199美元[5] 市场评级 - Leerink Partners维持对Hims股票的"市场表现"评级[5] - IBD SmartSelect综合评级从93分提升至96分[6] - 公司股价在不到4年内实现1600%涨幅 并获得90以上相对强弱评级[7]
Compared to Estimates, Synopsys (SNPS) Q3 Earnings: A Look at Key Metrics
ZACKS· 2025-09-09 22:31
财务表现 - 季度收入达17.4亿美元 同比增长14% 但低于市场共识预期1.77亿美元 实际收入较预期低1.61% [1] - 每股收益3.39美元 低于去年同期3.43美元 且较市场共识预期3.84美元低11.72% [1] - 维护与服务收入3.31亿美元 超出四位分析师平均预期2.9亿美元 同比增长18.2% [4] 业务细分 - 设计自动化业务收入13.1亿美元 大幅超越三位分析师平均预期的12.3亿美元 同比增长23.5% [4] - 设计IP业务收入4.28亿美元 低于三位分析师平均预期的5.39亿美元 同比下降7.7% [4] - 前期产品收入5.16亿美元 略低于三位分析师平均预期的5.33亿美元 但同比增长16.7% [4] 市场表现 - 过去一个月股价下跌1.1% 同期标普500指数上涨1.9% 表现弱于大盘 [3] - 当前Zacks评级为4级(卖出) 预示近期可能继续跑输大市 [3] - 时间型产品收入8.92亿美元 低于三位分析师平均预期的9.46亿美元 但同比增长11.1% [4]